This research study will enroll people who have multiple myeloma, mantle cell lymphoma, or diffuse large B cell lymphoma. Patients will receive i.v. infusions of a new investigational medication (SNS01-T) twice weekly for six weeks and then be evaluated monthly for up to six months. The main purpose is to determine whether the investigational agent is safe and tolerable. The study also will look for any effectiveness of SNS01-T and will measure how it is processed by the body.
Qualified Participants Must:
Have a diagnosis of Multiple Myeloma, Mantle Cell Lymphoma or Diffuse Large B Cell Lymphoma
Have received at least two treatment regimens for their disease from which they either relapsed or did not respond
Have previously received the standard therapies for their disease
Have measurable disease
Not be currently receiving other anticancer treatments or investigational therapies
Be at least 18 years of age or older